'Mad Money' Lightning Round: SunTrust Banks Is Terrific
at The Street - Wed Dec 24, 5:00AM CST
Cramer says by GW Pharmaceuticals for the long term but avoid Arlington Asset Management and Prospect Capital.
EYES: 11.01 (+0.86), GWPH: 68.08 (+1.82), COG: 30.21 (-0.39), STI: 42.43 (-0.18), AI: 27.70 (-0.12), BMY: 59.15 (-0.01), RRC: 55.73 (-1.27), PSEC: 8.59 (-0.02)
Cramer's Lightning Round - GW Pharmaceuticals Is A Great Stock For The Long Term (12/23/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Dec 24, 4:41AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday December 23. Bullish Calls: GW Pharmaceuticals (NASDAQ: GWPH ): "It is very speculative, but it is a hold for the long term. GWPH has these...
EYES: 11.01 (+0.86), COG: 30.21 (-0.39), GWPH: 68.08 (+1.82), STI: 42.43 (-0.18), AI: 27.70 (-0.12), PSEC: 8.59 (-0.02)
Jim Cramer's 'Mad Money' Recap: Here Are 10 Stocks to Buy on Strong GDP Data
at The Street - Tue Dec 23, 7:26PM CST
Kimberly-Clark, Walgreen and Starbucks are among Cramer's winners on today's GDP number.
RH: 96.97 (-0.16), EYES: 11.01 (+0.86), ETN: 69.30 (-0.09), HON: 101.96 (-0.02), KMB: 117.77 (-0.21), IBB: 299.80 (+5.12), BMY: 59.15 (-0.01), PLKI: 55.50 (+0.01), MAR: 78.35 (-0.19), BA: 131.24 (+1.21), RRC: 55.73 (-1.27), VSAT: 63.75 (-0.20), SBUX: 81.27 (-0.16), NVGS: 20.00 (+2.10), COG: 30.21 (-0.39), GILD: 91.29 (+1.84), GWPH: 68.08 (+1.82), STI: 42.43 (-0.18), COST: 143.65 (-0.50), AI: 27.70 (-0.12), WAG: 76.67 (+0.16), PSEC: 8.59 (-0.02), EPD: 35.45 (+0.25)
3 Drugmakers Facing a Pivotal 2015
George Budwell, The Motley Fool - Motley Fool - Mon Dec 22, 10:41AM CST
Source: www.bio.org Pharmaceutical companies have been some of the best performing stocks lately due to the confluence of an aging U.S. population and new regulatory avenues within the Food and Drug Administration that have led to an uptick in drug...
BIIB: 340.89 (+5.13), ISIS: 59.49 (+1.88), GWPH: 68.08 (+1.82), AZN: 70.44 (+0.26), IBB: 299.80 (+5.12), PTCT: 51.66 (+0.76), GSK: 42.85 (+0.11)
GW Pharmaceuticals Added to NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 22, 1:00AM CST
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective at the open of U.S. markets today.
GWPH: 68.08 (+1.82), IBB: 299.80 (+5.12)
Could the Next Generation of Diabetes Treatments Be Found in This Illegal Drug?
Sean Williams, The Motley Fool - Motley Fool - Sun Dec 21, 10:41AM CST
Heart disease and cancer may be the two most common direct causes of death in the United States, but a chronic disease that now affects 29.1 million people in this country and is a prime risk factor for heart disease, cancer, and...
JNJ: 104.59 (+0.31), GWPH: 68.08 (+1.82), MRK: 57.46 (+0.25), MNKD: 5.68 (+0.18)
A New Study on Diabetes Reveals Potentially Frightening News
Sean Williams, The Motley Fool - Motley Fool - Sat Dec 20, 10:41AM CST
Based on the latest statistics from the CDC, 29.1 million people in the U.S. now have diabetes, of which more than one in four is unaware they have the chronic disease. This is up from 26 million in the CDC's last update. Further, the number of...
JNJ: 104.59 (+0.31), GWPH: 68.08 (+1.82), AZN: 70.44 (+0.26), MNKD: 5.68 (+0.18)
BreedIT and Seach Leverage Designer Strains to Better Cure
ACCESSWIRE - Thu Dec 18, 8:40AM CST
WHITEFISH, MT / ACCESSWIRE / December 18, 2014 / The benefits of medical cannabis are becoming increasingly apparent as companies like GW Pharmaceuticals plc (NASDAQ: GWPH) publish the results of the clinical trials for their cannabinoid-based medicines. For example, their Epidiolex has shown tremendous potential in treating Dravet and Lennox-Gastaut syndromes.
GWPH: 68.08 (+1.82)
U.S. Legalized Cannabis Industry Estimated to be Worth Over $2 Billion in 2014 as Licensed Medical Marijuana Operators Grow Exponentially
PR Newswire - Thu Dec 18, 7:45AM CST
The cannabis retail market is expected to reach $12 billion by 2020 as America moves towards legalized marijuana state by state. Companies in focus today are: Zoned Properties, Inc. (OTC: ZDPY), Medbox, Inc. (OTC: MDBX), GW Pharmaceuticals plc (NASDAQ: GWPH), Vape Holdings Inc. (OTC: VAPE) and Terra Tech Corp. (OTC: TRTC)
GWPH: 68.08 (+1.82)
Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 88.76 (+3.23), BMRN: 88.18 (+0.89), TGTX: 16.03 (+0.33), BMY: 59.15 (-0.01), MACK: 10.91 (+0.36), FMI: 23.99 (-0.10), RNA: 18.76 (+0.10), GWPH: 68.08 (+1.82), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), ICPT: 151.49 (+5.85), THLD: 2.93 (+0.01), CEMP: 20.66 (+0.78), NVS: 93.91 (+0.66)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
How to Buy Great Healthcare Stocks
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Fri Dec 12, 12:22PM CST
Not every investor interested in the healthcare sector has personal expertise in the field. Foolish Analyst Michael Douglass and Contributor Todd Campbell share some of the perks and pitfalls of investing in healthcare companies, from retail to big...
GWPH: 68.08 (+1.82), CVS: 97.89 (+0.02), WAG: 76.67 (+0.16), RAD: 7.26 (-0.09), CELG: 109.60 (+3.48)
Covidien Loses $176M Award in Patent Case Against JNJ Unit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 5:45PM CST
The patent infringement war between Covidien plc (COV) and Ethicon Endo-Surgery Inc. received a fresh ruling from the top U.S. patent appeals court last Thursday.
ICUI: 83.38 (+1.63), JNJ: 104.59 (+0.31), GWPH: 68.08 (+1.82), COV: 103.35 (+0.57)
RedHill submits MAA for ondansetron
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:38AM CST
INSY: 41.52 (+0.51), TSRO: 36.80 (+0.57), HRTX: 9.75 (+0.02), RDHL: 12.22 (-0.13), GWPH: 68.08 (+1.82), OPK: 9.63 (+0.21), GALE: 1.49 (-0.02)
Why GW Pharmaceuticals Is Currently The Only Game In Town For A Cannabis Play
Nick Cox - at Seeking Alpha - Mon Dec 08, 10:59AM CST
INSY: 41.52 (+0.51), GWPH: 68.08 (+1.82)
Novus Becomes an Insurance Leader as MMJ Market Approaches Tipping Point
ACCESSWIRE - Mon Dec 08, 9:21AM CST
WHITEFISH, MT / ACCESSWIRE / December 8, 2014 / A unique company in the MMJ space today that is focused on the medical insurance side of the business is Novus Acquisition & Development (OTC: NDEV). Novus provides health insurance and insurance related solutions to the growing wellness and MMJ markets using an innovative cost-saving provider network model that is administered via their wholly-owned Novus Medical Group subsidiary's Novus MedPlan. The timely rollout of the Novus MedPlan in states where MMJ is legal, which gives patients access to considerable discounts on MMJ products for a modest subscriber fee of under $20 a month, was recently highlighted in Forbes as the number one pick, taking the top slot out of a list of the eight hottest publicly traded companies to draw the interest of investors in this rapidly emerging sector.
CARA: 9.78 (+0.02), INSY: 41.52 (+0.51), GWPH: 68.08 (+1.82)
American Cannabis Helps Navigate the Cannabis Industry
ACCESSWIRE - Mon Dec 08, 8:55AM CST
WHITEFISH, MT / ACCESSWIRE / December 8, 2014 / The U.S. cannabis industry could be worth $35 billion in 2020 if all 50 states legalized the drug and the federal government ended its prohibition, according to a report from GreenWave Advisors. Even if the federal government doesn't end prohibition and the trajectory of legalization continues on its path, the industry could still reach $20 billion in size by the analyst's estimate.
GWPH: 68.08 (+1.82), TWD.VN: 2.000 (-0.020)
American Cannabis Company, A Delaware Corporation, Joins The List Of At Least 46 Other Marijuana Stocks
Anthony Cataldo - at Seeking Alpha - Sun Dec 07, 5:36PM CST
GWPH: 68.08 (+1.82), FULL: 4.76 (-0.01)
Could Marijuana Be the Answer to Fighting This Deadly Disease?
Sean Williams, The Motley Fool - Motley Fool - Sun Dec 07, 10:41AM CST
Source: Flickr user James St. John. The midterm elections may be over, but the jockeying over marijuana's ultimate fate as a medical -- and recreational -- drug hasn't died down one bit. Marijuana's enormous market potential Over the past...
GWPH: 68.08 (+1.82), LLY: 70.16 (+0.42)